Compare Abeona Therapeutics Inc (ABEO) vs Arko Corp. (ARKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Arko Corp. — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Arko Corp. trades at $8.05 (market cap $880.66M). The key difference: Arko Corp. is far larger — about 2.4× Abeona Therapeutics Inc's market cap, and Arko Corp. pays a 1.53% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ARKO | |
|---|---|---|
Market Cap | $373.32M | $880.66M |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $8.64 |
52-Week Low | $4.17 | $3.82 |
Enterprise Value | $228.22M | $3.05B |
Dividend Yield | — | 1.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ARKO trades at $7.85, down 2.36% today, with a bullish technical signal from moving averages. The company reported Q1 2026 earnings of -$0.07 per share, beating expectations, but revenue has declined from $9.4B in 2023 to $7.6B in 2025. Net income margin remains thin at 0.38%, while the P/E ratio of 39.75 suggests high earnings expectations relative to current profits. Recent news highlights ARKO as a defensive pick amid inflation concerns.
The outlook is mixed: positive technical momentum and defensive stock characteristics offer upside, but weak revenue growth and low profitability pose risks. All covering analysts rate it Hold, indicating caution. Investment appeal hinges on margin improvement and stable cash flow to support dividends, though high debt and economic sensitivity remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →
